RevisionCommentarymCRPC11th July for SRO.pdf (228.95 kB)
No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer
journal contribution
posted on 2023-06-09, 02:23 authored by Valerie JenkinsValerie Jenkins, Lesley FallowfieldLesley FallowfieldThe majority of men treated for prostate cancer will eventually develop castrate resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual’s information needs at all stages of disease are assessed, and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately we conclude that there is still a lack of good quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required.
Funding
EXPECT; G1580; pH Associates and Sanofi
History
Publication status
- Published
File Version
- Accepted version
Journal
Supportive Care in CancerISSN
0941-4355Publisher
Springer VerlagExternal DOI
Issue
11Volume
24Page range
4471-4473Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2016-08-04First Open Access (FOA) Date
2017-07-29First Compliant Deposit (FCD) Date
2016-08-04Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC